[{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"8edf0eb7-d0e0-49b2-b787-cd7e18808b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT02597946","created_at":"2021-01-18T12:36:41.049Z","updated_at":"2025-02-25T14:00:49.865Z","phase":"Phase 2","brief_title":"Afatinib in NSCLC With HER2 Mutation","source_id_and_acronym":"NCT02597946","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • KIT","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2 • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 07/22/2018","primary_completion_date":" 07/22/2018","study_txt":" Completion: 07/22/2018","study_completion_date":" 07/22/2018","last_update_posted":"2025-02-19"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"b7d5c857-2d6d-49ee-a382-780def97434a","acronym":"SOHO-01","url":"https://clinicaltrials.gov/study/NCT05099172","created_at":"2021-10-29T14:53:14.073Z","updated_at":"2025-02-25T15:35:22.229Z","phase":"Phase 1/2","brief_title":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)","source_id_and_acronym":"NCT05099172 - SOHO-01","lead_sponsor":"Bayer","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hyrnuo (sevabertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-11"},{"id":"4e3eec72-a814-4c0e-9cb1-d5be450dc993","acronym":"BEAMION-Lung 1","url":"https://clinicaltrials.gov/study/NCT04886804","created_at":"2021-05-14T12:52:37.162Z","updated_at":"2025-02-25T15:35:04.451Z","phase":"Phase 1","brief_title":"Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","source_id_and_acronym":"NCT04886804 - BEAMION-Lung 1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NRG1","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hernexeos (zongertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 554","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-10"},{"id":"45310b86-8e89-4f40-b34a-2e13d9ccd8c4","acronym":"DESTINY-LUNG02","url":"https://clinicaltrials.gov/study/NCT04644237","created_at":"2021-01-19T20:39:17.223Z","updated_at":"2025-02-25T14:59:31.216Z","phase":"Phase 2","brief_title":"Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04644237 - DESTINY-LUNG02","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 152","initiation":"Initiation: 03/19/2021","start_date":" 03/19/2021","primary_txt":" Primary completion: 12/23/2022","primary_completion_date":" 12/23/2022","study_txt":" Completion: 08/23/2024","study_completion_date":" 08/23/2024","last_update_posted":"2024-10-24"},{"id":"7b8a02fc-93ba-4510-a730-5331f3179340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04147819","created_at":"2021-01-18T20:19:04.190Z","updated_at":"2025-02-25T17:11:00.786Z","phase":"Phase 1","brief_title":"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein","source_id_and_acronym":"NCT04147819","lead_sponsor":"Bayer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY2701439 • BAY2701438"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2024-09-27"},{"id":"f5068016-59e0-4acd-94dd-b75bbe855ac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04818333","created_at":"2021-03-26T14:52:26.950Z","updated_at":"2024-07-02T16:34:26.372Z","phase":"Phase 1/2","brief_title":"A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04818333","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 157","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-13"},{"id":"c2c84b92-978f-421a-b60b-23ef961d4d07","acronym":"DESTINY-Lung04","url":"https://clinicaltrials.gov/study/NCT05048797","created_at":"2021-09-17T15:55:05.258Z","updated_at":"2024-07-02T16:34:26.687Z","phase":"Phase 3","brief_title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","source_id_and_acronym":"NCT05048797 - DESTINY-Lung04","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 03/29/2027","study_completion_date":" 03/29/2027","last_update_posted":"2024-06-12"},{"id":"5281d885-db71-4720-b9bf-1c0b248f2e5b","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372614","created_at":"2022-05-13T12:54:23.489Z","updated_at":"2024-07-02T16:34:58.772Z","phase":"Phase 1","brief_title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","source_id_and_acronym":"NCT05372614 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD4 • CASP3","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA","tags":["HER-2 • CD4 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-06-05"},{"id":"0f37c89c-39bf-456d-8d8e-0fef0fe7675f","acronym":"WK-KONG1","url":"https://clinicaltrials.gov/study/NCT03974022","created_at":"2021-01-18T19:32:51.357Z","updated_at":"2024-07-02T16:35:03.473Z","phase":"Phase 1/2","brief_title":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","source_id_and_acronym":"NCT03974022 - WK-KONG1","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-05-15"},{"id":"14e3df84-b533-4173-b75c-16ee69ed3716","acronym":"","url":"https://clinicaltrials.gov/study/NCT06114511","created_at":"2023-11-02T15:12:55.772Z","updated_at":"2024-07-02T16:35:03.825Z","phase":"Phase 1/2","brief_title":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","source_id_and_acronym":"NCT06114511","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab brengitecan (BL-M07D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/24/2024","start_date":" 04/24/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-14"},{"id":"d86e0008-addd-46dd-a534-ed4464f394e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06058988","created_at":"2023-09-28T14:10:30.751Z","updated_at":"2025-02-25T15:01:06.305Z","phase":"Phase 2","brief_title":"Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer","source_id_and_acronym":"NCT06058988","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 09/22/2027","primary_completion_date":" 09/22/2027","study_txt":" Completion: 09/22/2027","study_completion_date":" 09/22/2027","last_update_posted":"2024-05-13"},{"id":"93361330-2005-437d-aa4d-2425a73c62f4","acronym":"REVERT","url":"https://clinicaltrials.gov/study/NCT05396807","created_at":"2022-05-31T12:54:44.367Z","updated_at":"2024-07-02T16:35:05.196Z","phase":"","brief_title":"REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients","source_id_and_acronym":"NCT05396807 - REVERT","lead_sponsor":"University of Rome Tor Vergata","biomarkers":" HER-2 • KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • HER-2 mutation","tags":["HER-2 • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • HER-2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-08"},{"id":"97ed81de-4986-4ca6-9f9a-c890f0cf6354","acronym":"","url":"https://clinicaltrials.gov/study/NCT05765851","created_at":"2023-03-13T15:02:22.751Z","updated_at":"2025-02-25T15:00:49.420Z","phase":"Phase 1","brief_title":"A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05765851","lead_sponsor":"Daiichi Sankyo","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 mutation • HER-2 expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1103"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-30"},{"id":"6ad9ed8c-e802-4c40-a19d-e01efe73e9ff","acronym":"DESTINY-Lung01","url":"https://clinicaltrials.gov/study/NCT03505710","created_at":"2021-01-17T17:11:34.942Z","updated_at":"2025-02-25T15:07:34.025Z","phase":"Phase 2","brief_title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03505710 - DESTINY-Lung01","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 181","initiation":"Initiation: 05/21/2018","start_date":" 05/21/2018","primary_txt":" Primary completion: 05/03/2021","primary_completion_date":" 05/03/2021","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2024-04-29"},{"id":"348b6bee-e334-487c-b8b5-38e99c466308","acronym":"ADELA","url":"https://clinicaltrials.gov/study/NCT06382948","created_at":"2024-04-24T17:32:40.686Z","updated_at":"2024-07-02T16:35:07.380Z","phase":"Phase 3","brief_title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","source_id_and_acronym":"NCT06382948 - ADELA","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Orserdu (elacestrant)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-26"},{"id":"a52c3104-0f9a-4050-865e-f342d9805c67","acronym":"HCCSC-C03","url":"https://clinicaltrials.gov/study/NCT05661357","created_at":"2022-12-22T15:59:20.868Z","updated_at":"2024-07-02T16:35:09.314Z","phase":"Phase 4","brief_title":"Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression","source_id_and_acronym":"NCT05661357 - HCCSC-C03","lead_sponsor":"Zhongnan Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Fruzaqla (fruquintinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-17"},{"id":"a8d677d0-5ee1-43b4-8222-8e26710de964","acronym":"DESTINY-Lung05","url":"https://clinicaltrials.gov/study/NCT05246514","created_at":"2022-02-18T13:52:38.995Z","updated_at":"2024-07-02T16:35:10.277Z","phase":"Phase 2","brief_title":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","source_id_and_acronym":"NCT05246514 - DESTINY-Lung05","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 09/23/2023","primary_completion_date":" 09/23/2023","study_txt":" Completion: 06/24/2024","study_completion_date":" 06/24/2024","last_update_posted":"2024-04-10"},{"id":"bea341dc-ce91-43e5-9281-085d350a6e88","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439136","created_at":"2021-01-18T21:22:05.787Z","updated_at":"2024-07-02T16:35:11.236Z","phase":"Phase 2","brief_title":"Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)","source_id_and_acronym":"NCT04439136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 01/22/2021","primary_completion_date":" 01/22/2021","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-04-05"},{"id":"00bd8728-3f59-46ec-9a86-63c1172937ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03807778","created_at":"2021-01-18T18:49:03.389Z","updated_at":"2024-07-02T16:35:14.426Z","phase":"Phase 1","brief_title":"A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03807778","lead_sponsor":"Takeda","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-15"},{"id":"3389546b-7889-41d7-a623-1ac7e9ef8f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05924256","created_at":"2023-06-29T14:09:00.727Z","updated_at":"2024-07-02T16:35:14.639Z","phase":"Phase 2","brief_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","source_id_and_acronym":"NCT05924256","lead_sponsor":"Fudan University","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-03-15"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"}]